Clinical and molecular diagnostic study of 320 Chinese children with epilepsy by Genome Sequencing,medRxiv - Genetic and Genomic Medicine

当前位置： X-MOL 学术 › medRxiv. Genet. Genom. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical and molecular diagnostic study of 320 Chinese children with epilepsy by Genome Sequencing
medRxiv - Genetic and Genomic Medicine Pub Date : 2020-07-20 , DOI: 10.1101/2020.07.16.20153254
Dongfang Zou , Lin Wang , Jianxiang Liao , Hongdou Xiao , Jing Duan , Tongda Zhang , Zhenzhen Yin , Jing Zhou , Haishen Yan , Yushan Huang , Jianbiao Li , Nianji Zhan , Ying Yang , Jingyu Ye , Fang Chen , Shida Zhu , Feiqiu Wen , Jian Guo

Purpose: To evaluate the diagnostic value of Genome Sequencing(GS) in children with epilepsy. Methods: We performed GS on 320 Chinese children with epilepsy and interpreted Single Nucleotide Variants (SNVs) and Copy Number Variant (CNVs) of all samples. The complete pedigree and clinical data of the probands were established and followed up. The clinical phenotypes, treatments, prognoses and genotypes of the patients were analyzed. Results: Pathogenic/likely pathogenic variants were found in 122 of 320 children (38.13%), of whom, 92 (28.8%) had SNVs, 27 (8.4%) had CNVs, and three had both SNVs and CNVs. Among these variants, there were 3 CNVs of <100K in length. The most frequently mutated gene was SCN1A (10.9%,10/92), which is related to Dravet Syndrome, followed by PRRT2 (8.7%,8/92), which is relevant to benign familial infantile epilepsy, TSC2 (7.6%,7/92), which is associated with Tuberous Sclerosis. The most common recurrent CNVs were 17p13.3 deletion (18.5%, 5/27), 16p11.2 deletion syndrome (14.8%, 4/27), 15q11.2 deletion (11.1%, 3/27), which are related to epilepsy, developmental retardation and congenital abnormalities. The diagnostic yield was higher as the age of seizure onset was smaller. The highest detection rate was 75% in whom developed seizures within one month after birth. 13.4% (43/320) cases were identified to be treatable based on GS. 1% (3/320) of epilepsy patients received direct therapeutic measures and demonstrated favorable prognosis. Conclusion: GS can complete the genetic diagnosis, individualized treatment, and family reproductive guidance for patients. GS can replace Exome Sequencing and Chromosomal Microarray Analysis and is expected to be the first choice of genetic testing method for patients with epilepsy. Key Words: epilepsy; Genome Sequencing; Copy Number Variant; seizure; Single Nucleotide Variations

更新日期：2020-07-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文